Plus therapeutics completes enrollment in second respect-lm phase 1 trial cohort of rhenium (¹⁸⁶re) obisbemeda for the treatment of leptomeningeal metastases

Topline feasibility, safety and biological response data from phase 1/part a anticipated in the second half of 2023 topline feasibility, safety and biological response data from phase 1/part a anticipated in the second half of 2023
pstv Ratings Summary
pstv Quant Ranking